Vestcor Inc Lowers Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)

Vestcor Inc decreased its holdings in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) by 52.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,832 shares of the company’s stock after selling 77,923 shares during the quarter. Vestcor Inc’s holdings in TriSalus Life Sciences were worth $74,000 at the end of the most recent quarter.

Separately, Bluefin Capital Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth approximately $189,000.

TriSalus Life Sciences Stock Up 2.2 %

Shares of TriSalus Life Sciences stock opened at $0.93 on Friday. The company has a fifty day moving average of $1.25 and a 200-day moving average of $1.36. TriSalus Life Sciences, Inc. has a 52-week low of $0.40 and a 52-week high of $2.23.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.